Lilly Stock Up as Investors Cheer Weight-Loss Drug Zepbound's Market Gains
• Eli Lilly's stock jumped 3.3% while overall market slumped • Investors enthusiastic about prospects for Lilly's weight-loss drug Zepbound • Analyst believes Zepbound taking market share from competitors like Novo Nordisk • Zepbound expected to drive $5 billion sales increase for Lilly in 2024 • Lilly stock has skyrocketed 70% in last year, some think valuation too high